• Oncology
  • Current

Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients.